<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02392494</url>
  </required_header>
  <id_info>
    <org_study_id>1075-002</org_study_id>
    <secondary_id>2015-000127-93</secondary_id>
    <nct_id>NCT02392494</nct_id>
  </id_info>
  <brief_title>Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)</brief_title>
  <official_title>A Single Rising Dose Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MK-1075 in HCV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and pharmacokinetics of MK-1075, and to
      determine the ability of MK-1075 to reduce HCV viral load, following administration of a
      single dose in HCV-infected participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants experiencing an adverse event (AE)</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma HCV ribonucleic acid (RNA) levels</measure>
    <time_frame>Up to Day 6</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>MK-1075 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV-infected participants will receive a single 100 mg dose of MK-1075.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-1075 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV-infected participants will receive a single 200 mg dose of MK-1075.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-1075 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV-infected participants will receive a single 400 mg dose of MK-1075.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-1075 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV-infected participants will receive a single 800 mg dose of MK-1075.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-1075</intervention_name>
    <description>MK-1075 will be supplied as 10 mg or 100 mg tablets for oral administration.</description>
    <arm_group_label>MK-1075 100 mg</arm_group_label>
    <arm_group_label>MK-1075 200 mg</arm_group_label>
    <arm_group_label>MK-1075 400 mg</arm_group_label>
    <arm_group_label>MK-1075 800 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female of non-child bearing potential

          -  In good health other than HCV genotype (GT) 1 infection

        Exclusion Criteria:

          -  Is mentally incapacitated or legally institutionalized

          -  Has a history of clinically significant and not stably controlled endocrine,
             gastrointestinal, cardiovascular, hematological, hepatic (excepting HCV infection),
             immunological, renal, respiratory, genitourinary or major neurological (including
             stroke and chronic seizures) abnormalities or diseases

          -  Has a history of cancer

          -  Is positive for hepatitis B surface antigen (HBsAg) or human immunodeficiency virus
             (HIV)

          -  Has participated in another investigational trial within 4 weeks (or 5 half-lives)
             prior to Screening

          -  Consumes &gt;2 alcoholic beverages a day or uses illegal drugs

          -  Has evidence or history of chronic hepatitis not caused by HCV including but not
             limited to non-HCV viral hepatitis, non-alcoholic steatohepatitis (NASH), drug-induced
             hepatitis, or autoimmune hepatitis

          -  Has clinical or laboratory evidence of advanced or decompensated liver disease,
             evidence of bridging fibrosis or higher grade fibrosis (Metavir score â‰¥3) from prior
             liver biopsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Moldova, Republic of</country>
  </removed_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>August 24, 2015</last_update_submitted>
  <last_update_submitted_qc>August 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

